- ADCelerate is supplying Phase I eligible Antibody-Drug Conjugate (ADC) drug substances and drug products for Investigational New Drug (IND) submission.
- Accelerates deadlines and allows faster delivery to patients in the clinic
- From project initiation to GMP drug in just 12 months
Mumbai, India, October 12, 2022 /PRNewswire/ — Piramal Pharma Solutions, a market-leading, patient-centric contract engineering and manufacturing company (CDMO), announced the launch of AD Acceleratea new branded solution for drug development of antibody-drug conjugates that shortens timelines for the development of initial clinical supply of both drug substance and drug product.
With AD Accelerate, Piramal Pharma Solutions (PPS) delivers fully developed manufacturing processes for antibody-drug conjugates and freeze-dried drugs within just twelve months. The program includes qualified, Phase I-qualified analytical methods to support batch release and stability studies for both the active substance and the drug, as well as data on the initial stability of the active substance (six months) and drug (one month).
Peter DeYoungChief Executive Officer, Piramal Pharma Solutions said, “As a CDMO serving the biopharmaceutical industry, we know that speed is key. Getting our clients to the clinic as quickly as possible without compromising quality supports our patient-centric ethos. AD Accelerate is a powerful example of this principle brought to life. By leveraging our skills and expertise in ADCs and sterile fill/finish, we are able to reduce schedules while maintaining the highest quality standards.”
The accelerated schedules that AD Accelerate Deliveries are made possible by PPS’ vast experience in solving antibody-drug conjugate problems as well as the company’s expertise in manufacturing lyophilized drugs. Although all are based on a standard process AD Accelerate The programs are adapted to the scope of the respective customer project.
learn more about it AD Accelerate,…
